Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis - Slideshow (NASDAQ:NKTR) 2026-02-10

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]